<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving DTD v1.0 20120330//EN" "JATS-journalarchiving.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0">
  <front>
    <article-meta>
      <title-group>
        <article-title>
          <bold id="bold-1">Expression of Pan-cytokeratin [Ae1/Ae3] in Oral Squamous Cell Carcinoma and Potential Malignant Oral Disorders- A Comparative Systematic Review</bold>
        </article-title>
      </title-group>
      <abstract>
        <p id="_paragraph-1"><bold id="bold-d259b7eb94469edc0e52f702cac03f4b">Int</bold><bold id="bold-2">r</bold><bold id="bold-3">oduction</bold><bold id="bold-4">:</bold><bold id="bold-5"> </bold>Intermediate filament and its prime role in the cytoskeleton involved in maintaining cell morphology, and is mainly observed in epithelial cells called as Cytokeratin. CKAE1/AE3 is a combination of two different clones of anti-CK monoclonal antibodies, a single reagent can be obtained with broad spectrum reactivity to high molecular weight and low molecular weight CK which can be used in different types of cancers or lesions. <bold id="bold-6">Aim</bold><bold id="bold-7">: </bold>To compare the expression of the CK-AE1/AE3 in oral squamous cell carcinoma (OSCC) and potentially malignant oral disorders (PMOD) through immunohistochemical method through a systematic review process. <bold id="bold-8">Materials and Methods: </bold>Articles or original studies related to the use of IHC marker AE1/AE3 in OSCC, malignant tumors and PMODs were selected for systematic review process. PUBMED and GOOGLE SCHOLAR were the search engines used for collection of articles. Keywords used were PAN CK [AE1/AE3], SCC, OSCC, PMOD. Articles included based on PRISMA guidelines. <bold id="bold-9">Results: </bold>A total article based on search strategy identified 492 suitable abstracts; 474 did not meet the eligibility criteria. Full text articles were obtained for 18 articles. Six articles were excluded from the study for various reasons like case reports, reviews and letters to editors and any article published in languages other than English were also excluded. Finally, after considering all the inclusion and exclusion criteria, a total of 12 articles were included in the study. Considering all these articles, comparing the expression of pan-cytokeratin [ae1/ae3] in oral squamous cell carcinoma and potential malignant oral disorders.</p>
      </abstract>
    </article-meta>
  </front>
  <body id="body">
    <sec id="heading-d33eb2f3a5fac6230f5b99cbbaf8b105">
      <title>Introduction</title>
      <p id="heading-cb759070b772b1967e3791578fd552be">Squamous cell carcinoma accounts for 90% of all oral malignant growths. It can affect any anatomical part of the mouth, but the most common are the tongue and the floor of the mouth. It usually comes from pre-existing potentially malignant lesions and sometimes can arise as an entirely new lesion; but in any case, it comes from the precancerous epithelium. well-known risk factors for oral squamous cell carcinoma are Tobacco and betel quid use, excessive consumption of alcoholic beverages, and low intake of fresh fruits and vegetables [1].</p>
      <p id="paragraph-2">The term “Potential Malignant Oral Disorder” (OPMD) was recommended by an international working group convened in London in 2005 by the World Health Organization (WHO) Collaborating Center for Oral Cancer and Precancerous Diseases. This suggests that not all diseases described as such will transform into invasive cancer. Leukoplakia, erythroplakia,oral submucosal fibrosis, lichen planus, palatal lesions in reverse smokers, actinic keratosis, discoid lupus erythematosus, congenital dyskeratosis, and epidermolysis bullosa are examples of potentially malignant oral disorders [2].</p>
      <p id="paragraph-76e6217651fff622679ab3d450a56cdd">Cytokeratin (CK) is an intermediate filament and is an important part of the cytoskeleton involved in maintaining cell morphology, and is mainly observed in epithelial cells. CKAE1/AE3 is a mixture of two different clones of anti-CK monoclonal antibodies. By combining these two reagents, a single reagent with broad spectrum reactivity to high molecular weight and low molecular weight CK can be obtained. In a study by Kaufmann et al, in dysplasia and carcinoma in situ, atypical cells show a response pattern in which there is loss or increased expression of AE1, which indicates that AE1 can be used as a biomarker to identify early aberrations in esophageal epithelial cancer [3].</p>
      <p id="paragraph-c2be74b11f23307c21c2876e3f23e787">This study is to compare the expression of the CK-AE1/AE3 in oral squamous cell carcinoma (OSCC) and potentially malignant oral disorders (PMOD) through immunohistochemical method through a systematic review process.</p>
    </sec>
    <sec id="heading-a2465a38b81bdad2c4746b584aa235ad">
      <title>Materials and Methods</title>
      <p id="paragraph-1">In this study, a systematic review has been performed by considering AE1/AE3 as a diagnostic histochemical marker in both OSCC and PMOD.</p>
      <p id="paragraph-d4dd7e078c5799029f1caaf2f73a073e">To answer the question of whether AE1/AE3 can be used as a diagnostic marker in PMODs, the literature search using a combination of keywords was done. PUBMED and GOOGLE SCHOLAR were the search engines that were used for collection of articles. Keywords used were PAN CK [AE1/AE3], SCC, OSCC, PMOD.</p>
      <p id="paragraph-3">Only invitro studies conducted in humans for the past 15 years were included in the study.</p>
      <sec id="heading-161cf1f19421e063098376027f407392">
        <title>
          <italic id="italic-1">Inclusion Criteria</italic>
        </title>
        <p id="paragraph-a233fac232eda80990f877a0b8eb16ce">1. ORIGINAL STUDY related to the use of IHC marker AE1/AE3 in OSCC, malignant tumors and PMODs.</p>
        <p id="paragraph-00544539d733e44ad3f29954f51f71b3">2. Articles Published from 2005 to 2021.</p>
        <p id="paragraph-4" />
      </sec>
      <sec id="heading-88f654d1da606a5f1a4b04edd4b13638">
        <title>
          <italic id="italic-2">Exclusion Criteria</italic>
        </title>
        <p id="paragraph-6">1. Reviews, case reports, conference presentations.</p>
        <p id="paragraph-7">2. No full text</p>
        <p id="paragraph-8">3. Languages other than English</p>
        <p id="paragraph-9">4. Published before 2005</p>
        <p id="paragraph-10">The article has been written according to the PRISMA guidelines (Figure 1).</p>
        <fig id="figure-panel-a3276cfe28100b918181f94087207ef2">
          <label>Figure 1. Prisma Flow Chart</label>
          <caption>
            <title></title>
            <p id="paragraph-bcf337fa9ecc3f840285c1d761d0d2b6" />
          </caption>
          <graphic id="graphic-2ae5f686546e8a4b68fdb8a0dbdf8dff" mimetype="image" mime-subtype="jpeg" xlink:href="http://waocp.com/journal/fig/cc/APJCC_V7_i2_N12_2022_Fig_1.jpg" />
        </fig>
      </sec>
    </sec>
    <sec id="heading-b00acca01f3466d6e079bdf266609e98">
      <title>Results</title>
      <p id="paragraph-1a3e76c8b347e1b8f25663a83fcf949b">The keyword search strategy identified 492 suitable abstracts; 474 did not meet the eligibility criteria. Full text articles were obtained for 18 articles. Six articles were excluded from the study for various reasons like case reports, reviews and letters to editors and any article published in languages other than English were also excluded. Finally, after considering all the inclusion and exclusion criteria, a total of 12 articles were included in the study. Five studies were taken for OSCC, four studies related to Squamous Cell Carcinoma (SCC) occurring in other parts of the body like gastro-intestinal tract-colorectal, oesophagus and breast cancer, two for Oral Sub Mucous Fibrosis (OSMF) and one study related to leukoplakia. The different studies showed that the expression of CK [AE1/AE3] increased as the grade of the malignancy worsened, starting from the PMODs like OSMF and dysplasia to poorly differentiated SCC, corroborated by the weakly-positive staining of PMODs, positive staining by SCC and greatest intensity of immunological staining by poorly differentiated SCC (Table 1).</p>
      <table-wrap id="table-figure-d5517b9a12526879795ec62f60765949">
        <label>Table 1. Overview of Selected Studies</label>
        <caption>
          <title></title>
          <p id="paragraph-4fcb07598bec0fdb6be788608268342f" />
        </caption>
        <table id="table-1684e3ca893b07d04dc9db41751a3520">
          <tbody>
            <tr>
               <td>S.NO</td>
               <td>Year</td>
               <td>Country</td>
               <td>Author Name</td>
               <td>Sample Size</td>
               <td>Parameter <!--There should be a line-break here.-->Assessed</td>
               <td>Observation</td>
               <td>Inference</td>
            </tr>
            <tr>
               <td>1</td>
               <td>2016</td>
               <td>India</td>
               <td>Anand Bhadkariya<!--There should be a line-break here.--> et al [3] </td>
               <td>90</td>
               <td>CK <!--There should be a line-break here.-->AE1/AE3</td>
               <td>In aspirate cytology, <!--There should be a line-break here.-->Immunocytochemical (ICC) detection of CK of <!--There should be a line-break here.-->malignant cells with or without inflammatory and<!--There should be a line-break here.--> benign cells. Varied patterns of CK positivity on <!--There should be a line-break here.-->correlating with respect to cytological diagnosis.</td>
               <td>Malignant cells were positive about 40% cases<!--There should be a line-break here.--> for CK of which the most common pattern<!--There should be a line-break here.--> observed was diffuse cytoplasmic staining. <!--There should be a line-break here.-->66.6% cases of SCC were positive for diffuse <!--There should be a line-break here.-->pattern over-expression of CK was observed.</td>
            </tr>
            <tr>
               <td>2</td>
               <td>2016</td>
               <td>India</td>
               <td>Isha Dhawan<!--There should be a line-break here.-->et al [4] </td>
               <td>10</td>
               <td>OSCC -CK <!--There should be a line-break here.-->AE1/AE3</td>
               <td>Laboratory based, prospective study was conducted <!--There should be a line-break here.-->on 133 lymph nodes (LNs) harnessed from ten patients<!--There should be a line-break here.--> treated with radical neck dissection for primary OSCC. <!--There should be a line-break here.-->The LNs were subjected to serial sectioning at 100<!--There should be a line-break here.-->µm intervals. The usual Haematoxylin<!--There should be a line-break here.-->&amp;Eosin staining was done for sections and pan-CK <!--There should be a line-break here.-->and were analyzed for micrometastasis and isolated <!--There should be a line-break here.-->tumor cells according to criteria laid by Hermanek et al.</td>
               <td>The SS and immunohistochemistry (IHC) combined for using pan-CK (AE1/AE3) in this study established the presence of MM and ITC in 2.25% of the LNs diagnosed as negative on routine H&amp;E examination. The evaluation of deposition of occult<!--There should be a line-break here.-->metastatses resulted in upstaging of 33.33% of the patients.</td>
            </tr>
            <tr>
               <td>3</td>
               <td>2016</td>
               <td>India</td>
               <td>Vineeth Gupta <!--There should be a line-break here.-->et al [5]</td>
               <td>30 Biopsy <!--There should be a line-break here.-->Specimens</td>
               <td>CKs</td>
               <td>A pilot study of 15 patients clinically diagnosed <!--There should be a line-break here.-->with carcinoma and their paralleling mirror image sites <!--There should be a line-break here.-->were taken and stained using immunohistochemistry<!--There should be a line-break here.-->method for the CK, Ki-67 and p53 expression.</td>
               <td>Primary tumors showed strong positive <!--There should be a line-break here.-->staining for CK throughout the epithelium <!--There should be a line-break here.-->and malignant epithelial islands but absence<!--There should be a line-break here.--> of staining for Ki-67 and p53</td>
            </tr>
            <tr>
               <td>4</td>
               <td>2018</td>
               <td>China</td>
               <td>Xin Min<!--There should be a line-break here.-->Li et al [6]</td>
               <td>82 Primary esophageal <!--There should be a line-break here.-->small cell carcinoma</td>
               <td>PANCKs</td>
               <td>Eighty-two Primary Esophageal Small Cell <!--There should be a line-break here.-->carcinoma patients were identified from the <!--There should be a line-break here.-->esophageal and gastric cardia cancer database <!--There should be a line-break here.-->which was created by Henan Key<!--There should be a line-break here.-->Laboratory for Esophageal Cancer Research,<!--There should be a line-break here.--> Zhengzhou University. This retrospective study <!--There should be a line-break here.-->evaluated CK and vimentin protein expressions in PESC.</td>
               <td>In cytoplasm of epithelial component tumor cells positive pan-CKs AE1/ AE3 staining was evaluated, with a positive detection rate of 85.4% (70/82). AE1/AE3 positive staining seen in 19 cases, observed both<!--There should be a line-break here.-->in epithelial and spindle components (23.2%). However, there was no association of AE1/AE3 with factors such as gender, tumor location, age, gross appearance, lymph node metastasis and TNM staging.</td>
            </tr>
            <tr>
               <td>5</td>
               <td>2007</td>
               <td>India</td>
               <td>Ruchika Gupta<!--There should be a line-break here.-->et al [7]</td>
               <td>35 Spindle cell <!--There should be a line-break here.-->carcinoma patients</td>
               <td>CKs</td>
               <td>To find out the difference in immunohistochemical expression of CK, smooth muscle actin and<!--There should be a line-break here.-->vimentin and alterations in mutation of K-RAS oncogene between the two tumours, in an attempt to characterise Spindle cell Carcinoma. Standard avidin–biotin complex method was used to perform IHC analysis</td>
               <td>In the Spindle Cell Carcinoma group, CK positivity was significantly higher<!--There should be a line-break here.-->in epithelial areas (52.2%) than in spindle cell areas (16.1%), whereas vimentin was intense positive in spindle cell areas (18.7%) than epithelial areas (2.7%). Cells mixed between epithelial and spindle cell areas were consistently positive for both CK and vimentin.</td>
            </tr>
            <tr>
               <td>6</td>
               <td>2006</td>
               <td>Europe</td>
               <td>G Cserni <!--There should be a line-break here.-->et al [8] </td>
               <td>449 patients<!--There should be a line-break here.-->with lobular breast<!--There should be a line-break here.-->carcinoma</td>
               <td>CK</td>
               <td>This study aimed to assess the value of CK IHC for the detection of metastases in sentinel lymph nodes of patients with invasive lobular carcinoma. The use of IHC was to<!--There should be a line-break here.-->find the different metastases, and the involvement of non –sentinel lymph nodes were analysed in a<!--There should be a line-break here.-->multi-institutional cohort of 449 patients with lobular breast carcinoma, with staging of sentinel lymph node biopsy and routine a ssessment of the sentinel lymph nodes.</td>
               <td>Different type of sentinel lymph node involvement was seen in 189 patients (42%), there was increased frequency of with increasing tumour size. IHC used for identification of lymph node involvement 65 of these tumor cases: 17 of 19 isolated<!--There should be a line-break here.-->tumour cells, 8 of 106 larger<!--There should be a line-break here.-->metastases,40 of 64<!--There should be a line-break here.-->micrometastases, and were detected.</td>
            </tr>
            <tr>
               <td>7</td>
               <td>2020</td>
               <td>Santo Domingo</td>
               <td>Velicko Vranes <!--There should be a line-break here.-->et al [9]  </td>
               <td>102 breast carcinoma <!--There should be a line-break here.-->patients</td>
               <td>CK</td>
               <td>Prognostic model consists 102 breast carcinoma patients, along with distant metastasis occurrence as the endpoint. Complete intensity range (0–255) of pan CK digitized immunostaining was segmented into seven discrete narrow grey level ranges: 0–130, 130–160,<!--There should be a line-break here.-->160–180, 180–200, 200–220, 220–<!--There should be a line-break here.-->240, and 240–255. 33 major (Gray Level Co-occurrence Matter), fractal and first-order statistics computational analysis features used for detection.</td>
               <td>Moderate intensities were strongly associated with metastasis outcome; However, high intensities of pan CK immunostaining provided no prognostic value even after an exhaustive computational analysis.</td>
            </tr>
            <tr>
               <td>8</td>
               <td>2021</td>
               <td>Brazil</td>
               <td>B-T<!--There should be a line-break here.-->Rodrigues <!--There should be a line-break here.-->et al [10]</td>
               <td>15482 biopsy specimens of <!--There should be a line-break here.-->primary oral melanoma</td>
               <td>CK</td>
               <td>A total of 15,482 biopsy records from two Oral and Maxillofacial Pathology services in Brazil were analyzed. Complete cases oral<!--There should be a line-break here.-->melanomas were inspected and their demographic, clinical, histopathological data, treatment, and follow-up status were collected. In addition, IHC stains (pan-CK AE1/ AE3, CD45, α-SMA, vimentin,S-100 MelanA,protein,HMB-45, and Ki-67) were performed.</td>
               <td>Cases-5 males (71.4%) and 2<!--There should be a line-break here.-->females (28.6%), and 2.5:1 male-to-female ratio, mean age of<!--There should be a line-break here.-->58.0 ± 9.2 years (range:45-69 years).<!--There should be a line-break here.-->Most commonly affected were gingiva (n = 3, 42.8%)<!--There should be a line-break here.-->and hard palate (n = 2, 28.6%).</td>
            </tr>
            <tr>
               <td>9</td>
               <td>2005</td>
               <td>China</td>
               <td>Zhi-Wei Zhou<!--There should be a line-break here.-->et al [11]</td>
               <td>114 patients with colorectal cancer</td>
               <td>CK</td>
               <td>This study aimed to detect lymph nodes micrometastases and analyze its correlation with clinicopathological parameters in Dukes’ A and B colorectal cancer patients. 114<!--There should be a line-break here.-->patients with colorectal cancer (Dukes’ A 16; Dukes’ B 98) undergone curative operation without histological lymph nodes metastases were studied between 2001 and 2003.<!--There should be a line-break here.-->From histopathological archieves, A total of 2,481 lymph node2 481 lymph nodes were determined using monoclonal CK antibody AE1/AE3<!--There should be a line-break here.-->(DAKO, Carpinteria, CA) for immunohistochemistry. </td>
               <td>In total, 33 (29%) patients were positive for cancer cell by immunohistochemistry.</td>
            </tr>
            <tr>
               <td>10</td>
               <td>2004</td>
               <td>Craiova</td>
               <td>Mălin RD <!--There should be a line-break here.-->et al [12]</td>
               <td>24 cases</td>
               <td>CK7, CK19, CK20,<!--There should be a line-break here.-->CKAE1/AE3,<!--There should be a line-break here.-->CK34betaE12, TTF1,<!--There should be a line-break here.-->HBME-1, CEA, MUC5AC<!--There should be a line-break here.-->and EBV.</td>
               <td>This study found that all ENT primary tumor with Lymph node metastases were positive for CKAE1/ AE3; CKAE1/AE3 negativity was<!--There should be a line-break here.-->seen in adenocarcinomas and CKAE1/ AE3 positivity in squamous carcinomas.</td>
               <td>From the immunohistochemical point of view, the esophageal carcinoma was positive for CKAE1/ AE3, while the gastric adenocarcinoma was positive for CEA.</td>
            </tr>
            <tr>
               <td>11</td>
               <td>2004</td>
               <td>London</td>
               <td>M Farrar <!--There should be a line-break here.-->et al [13]</td>
               <td>10</td>
               <td>AE1/AE3, CK [CK] 14, Ki-67<!--There should be a line-break here.-->and p53</td>
               <td>In this study, a panel of monoclonal antibodies (AE1/AE3, CK [CK] 14, Ki-67 and p53) in 10 cases of human oral tissue in each of six variants to obtain staining patterns.</td>
               <td>The results showed that AE1/AE3 and CK 14 expression was reduced as a late event in oralcarcinogenesis, particularly in poorly differentiated SCC.Expression of Ki-67 and p53 proved to be a poor but statistically significant predictor of malignant progression.</td>
            </tr>
            <tr>
               <td>12</td>
               <td>2006</td>
               <td>India</td>
               <td>K<!--There should be a line-break here.-->Ranganathan<!--There should be a line-break here.--> et al [14]</td>
               <td>60</td>
               <td>PanCK AE1/AE3 (1–8, 10,<!--There should be a line-break here.-->13–16 and<!--There should be a line-break here.-->19)</td>
               <td>Significant difference in the CK staining pattern was seen among normal, OSMF and cancer tissues. Significant changes in OSMF included increased intensity of staining for PanCK and High Molecular Weight Cytokeratin, CK8 abnormal expression and decreased expression of CKs 5 and 14.</td>
               <td>CK profile of OSMF was significantly varies from normal for PanCK, HMWCK, CK8,5 and 14<!--There should be a line-break here.-->suggesting the latter’s potential to be used as surrogate markers of malignant transformation.</td>
            </tr>
          </tbody>
        </table>
      </table-wrap>
      <p id="paragraph-1346ad3282ca5fc29d6fbc98fd37717e">MM, Micro metastasis; ITC, isolated tumor cells; H&amp;E, Haematoxylin and Eosin; PESC, Primary esophageal small cell carcinoma; Pan CK, Pan cytokeratin; SMA, Smooth muscle actin; HMB, human melanoma black; PCNA, Proliferating cell nuclear antigen; VEGF, Vascular endothelial growth factor; HMWCK, High molecular weight cytokeratin</p>
    </sec>
    <sec id="heading-73ea52cf17cc7b9b3db910b2a5aee283">
      <title />
    </sec>
    <sec id="heading-507888693a97464fb41bd599082c1884">
      <title>Discussion </title>
      <p id="paragraph-b6896354dadf30e78bce2fd5054944d5">In India oral tumors constitutes 30% of all malignancies and of these 90% are OSCC. Some of the oralcarcinomas arise from pre-existing,pre-cancerous lesions such as OSMF and leukoplakia. However, the malignant conversion rate of pre cancerous lesion ranges from 8% to 10%. Recently, it has been found that even the clinically normal appearing mucosa in a patient. Dysplasia may be observed in cancerous lesion and on the contra lateral anatomic site. To study histopathologic changes that are observed in mucosa opposite to oral cancers,tumor markers play an important role in differentiating a normal tissue from cancerous tissue. </p>
      <p id="paragraph-7f9ec3f3d6662a254198fd520bd66f8b">Pan CK (pan CK) (AE1/AE3) can be used to identify a wide spectrum of both acidic and basic cytokeratin’s and is commonly used as an prime marker to differentiate epithelial tumors from the nonepithelial ones with a high degree of accuracy even under low power standard light microscope. Since pan CK [AE1/AE3] is an epithelial marker it shows positivity for majority of epithelial tumors, more commonly in OSCC and PMODs.It has been shown that changes in the underlying connective tissue are reflected in the adjacent epithelium and also result in alterations in CKexpressions.</p>
      <p id="paragraph-34452d6b95f7a2fe95689cb93955866d">In a study done by G Cserni et al, AE1/AE3 immunostaining in the basal layer was negative in the majority of cases except in severe dysplasia where 50% of cases showed a positively stained basal layer. CK 5 and CK 14 form the CK network in the basal layer. Reduced expression of one of this pair of CKs could result of stratified squamous epithelium.14in the reduced detection of the other. The CK 14 positivity was confirmed by the immunostaining results, showing expression in the basal layer in all cases studied. Therefore, the lack of basal layer staining could represent a reduction in CK 5 expression frequently at an earlier stage in malignant transformation, reducing the detection by AE1/AE3 antibody of CK 14 expression [8].</p>
      <p id="paragraph-35f416229c81e9dbe05a5b78a5e96ab3">AE1/AE3 antibody proved helpful in detecting malignant changes in clinically normal appearing mucosa (mirror image biopsy) in OSCC. For CK AE1/AE3, out of 7 cases, showing strong positive staining, one case showed more positivity in stratum spinosum and stratum superficiale and less intense staining in stratum granulosum and basale. This may be due to same pattern of keratin expression in stratum superficiale and stratum spinosum.</p>
      <p id="paragraph-0e4a5c584da1add4629bfe5bd56de7b1">OSCC commonly metastasizes to the regional lymph nodes which are the first sites for tumor cells arrest that have invaded the peritumoral lymphatics and hence the strongest indicator of disease prognosis and outcome. For identification of an epithelial component, a mixture of antibody clones can be applied depending on its origin. The clones such as KL1, MNF116 and AE1/ AE3 employed for detection of epithelial tumors.KL1 is recommended for detection of CKs 1, 2, 5, 6, 7, 8, 11,14, 16, 17 and 18. Pan-CK is highly useful for screening of nodal micro metastasis MM even when low-power standard light microscopic examination is employed. Hence, this marker was preferred over other markers for detection of MICROMETASTASIS and ISOLATED TUMORCELLS [5].</p>
      <p id="paragraph-1f586aa32998aacc6160bb1f34f65768">Spindle Cell Carcinoma (SpCC) has been represented as a biphasic tumour with a common site to be affected was the upper aerodigestive tract. In a study by Ruchika Gupta et al reported three tumour-cell markers to which IHC analysis were done: CK, vimentin and smooth-muscle actin were done. CK positive was significantly greater in SCC than in spindle cell and squamous cell components of SpCC. The squamous cell areas of this carcinoma had a greater mean positivity for CK. The spindle cell areas plump to oval cells with nuclei elongated intermixed exhibiting both CK and vimentin positivity [7].</p>
      <p id="paragraph-e9488cc0c16f8c0af2890431090af369">CK positive nodal structures cannot be equated with metastatic nodal involvement always. Normal components of the lymph nodes may also stain with anti-CK antibodies. Plasma cells have also been reported to stain with CAM5.2 [monoclonal antibody] and in IHC, pan CK of unselected axillary lymph nodes from patients with Invasive Lobular Carcinoma has been shown to upstage these patients more often than those with ductal carcinoma [8].</p>
      <p id="paragraph-19481a7ef4268f9a5f9997132c22a49a">CK and vimentin protein expression is a useful biomarker for PESC accurate diagnosis, but not prognosis. The present results demonstrate that CK, expressed chiefly in epithelial tumor cells, and vimentin, expressed always in spindle tumour cells, are useful diagnostic biomarkers in PESC, especially, the predictive power of the AE1/AE3 and vimentin proteins together was increased apparently than with single protein. However, the AE1/ AE3, CK5/6 and vimentin proteins expressions didn’t show any remarkable effects on PESC survival. Furthermore, no relationship was observed for the AE1/AE3 and vimentin proteins expression and age, gender, tumor location, gross appearance, lymph node metastasis, and TNM stage [6]. In SCC, recently immunocytochemical techniques have become widely used in cytopathology for the demonstration of a large number of various antigens (e.g., p53, CEA, EMA, LeuM1, B72.3, Lectin, CK, vimentin etc) in effusion and aspirate as an aid in differentiating malignant cells from benign cells. The detection of CK intermediate filament is widely used to identify tumors of epithelial origin. In present study CK positivity is found in 08/12 (66.66%) squamous cell carcinoma from aspirates [3].</p>
      <p id="paragraph-3e7bbc16c9f7f1be2d9fd59b8388b219">In Colorectal cancer, monoclonal cytokeratin antibody AE1/AE3 to detect lymph node micrometastasis in Dukes’ A and B colorectal cancer patients by using Immunohistochemistry. These patients usually treats with curative operation without any discovery of lymph nodes metastases using conventional histological techniques in the resected specimens. The results suggested that occult cancer cells were significantly stained with anti-CK antibody.</p>
      <p id="paragraph-5">Over expression of panCK [AE1/AE3] can be used as a potential tool in diagnosis and hence used as a diagnostic marker. It is also used to see the progression of OSCC in response to specific treatment; so, it can also be used as prognostic marker. The advantage of this marker is, it has a high specificity, high sensitivity, long lead time, levels correlate with tumor burden, it has a short half-life, it is simple and cheap to test and it can be easily obtained. More studies are definitely needed in future with panCK [AE1/AE3] in PMODs, especially in different grades of severity of these, to have an excellent database for comparative and analytical studies.</p>
      <p id="paragraph-84cabfbb09d5244a09c1529e0fb55249">More studies are also needed with regard to the TNM- staged OSCC and different grades of OSCC so that this maker can serve as a fool proof method in prognosis. The antibody reviewed in this study-panCK [AE1/AE3] constitutes a satisfactory diagnostic panel for assessing benign and premalignant oral lesions as they provide information about epithelial differentiation, proliferation, and cell-cycle regulation. AE1/AE3 antibody is not a useful marker in assessing tumour invasion as it does not stain the basal layer in all cases. It is a satisfactory marker of squamous epithelium and has a useful application in distinguishing between SCC and malignancies of non-epithelial origin.</p>
      <p id="paragraph-01b1cce045bb3de172f46644fb0309a5">In conclusion, Thus, the current systematic review depicts the importance of the pan-CK marker-AE1/ AE3 as a very crucial tumormarker. Though it is a very often-researched marker as far as SCC is concerned, studies are limited with regard to the same in PMODs. This review tends to point towards this lacuna, which if addressed, will showcase this marker as a very potent diagnostic and prognostic marker. The quality and quantity of its expression can serve as a map to target the therapies towards reversibility of PMODs and a quicker remission of frank malignancies. Also, innovative studies, in the same direction can be conducted and are needed in other epithelial potentially malignant lesions/conditions and tumors- benign/malignant like ameloblastoma, salivary gland tumors, extra-oral lesions etc.</p>
      <p id="paragraph-9b6d09f538de1554c2144b14d2100191" />
      <p id="paragraph-e36d6ce7333c1a98d52c65f70b43c2c0">
        <italic id="italic-0bacaddb3fe1b1485864b2c58298c27e">Conflict of Interest Statement</italic>
      </p>
      <p id="paragraph-abd60d06e195e978ada564b1fbe8a362">The authors had no conflict of interest concerning the topic under consideration in this article.</p>
      <p id="paragraph-1b9be1b5a2215ebfe8a99bd77d5e3ca0" />
    </sec>
    <sec id="heading-722253db39c9664baf899137a9b9135b">
      <title>References</title>
    </sec>
  </body>
  <back>
    <ref-list>
      <ref id="journal-article-ref-5d7d90ab152bbe3f540e0b56937d85eb">
        <element-citation publication-type="journal">
          <day>09</day>
          <issue>4</issue>
          <month>08</month>
          <page-range>263-268</page-range>
          <volume>3</volume>
          <year>2012</year>
          <pub-id pub-id-type="doi">10.4236/jct.2012.34037</pub-id>
          <person-group person-group-type="author">
            <name>
              <surname>Feller</surname>
              <given-names>Liviu</given-names>
            </name>
            <name>
              <surname>Lemmer</surname>
              <given-names>Johan</given-names>
            </name>
          </person-group>
          <source>Journal of Cancer Therapy</source>
          <article-title>Oral Squamous Cell Carcinoma: Epidemiology, Clinical Presentation and Treatment</article-title>
        </element-citation>
      </ref>
      <ref id="journal-article-ref-48dd22f1da429f588a24d49ef098cba7">
        <element-citation publication-type="journal">
          <issue>1</issue>
          <month>10</month>
          <volume>57</volume>
          <year>2011</year>
          <pub-id pub-id-type="doi">10.1111/j.1600-0757.2011.00401.x</pub-id>
          <person-group person-group-type="author">
            <name>
              <surname>Nw</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>P</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Aa</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <source>Periodontology 2000</source>
          <article-title>Squamous cell carcinoma and precursor lesions of the oral cavity: epidemiology and aetiology</article-title>
        </element-citation>
      </ref>
      <ref id="journal-article-ref-042c60122a391c9be14cd132b252c1fa">
        <element-citation publication-type="journal">
          <year>2016</year>
          <pub-id pub-id-type="doi">10.5958/2394-6792.2016.00004.1</pub-id>
          <person-group person-group-type="author">
            <name>
              <surname>Bhadkariya</surname>
              <given-names>Anand</given-names>
            </name>
            <name>
              <surname>Ramchandani</surname>
              <given-names>Abhiraj</given-names>
            </name>
            <name>
              <surname>Patel</surname>
              <given-names>Swati</given-names>
            </name>
            <name>
              <surname>Purohit</surname>
              <given-names>Manju</given-names>
            </name>
          </person-group>
          <source>Indian Journal of Pathology and Oncology</source>
          <article-title>Study of Cytokeratin AE1/AE3 Reactivity in Squamous cell carcinoma in aspiration cytology</article-title>
        </element-citation>
      </ref>
      <ref id="journal-article-ref-ee7369656c7ea20810b3b7df3777cad5">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Isha</surname>
              <given-names>D</given-names>
            </name>
            <collab>
              <named-content content-type="name">Simarpreet VS</named-content>
            </collab>
            <name>
              <surname>Rajat</surname>
              <given-names>B</given-names>
            </name>
            <collab>
              <named-content content-type="name">NeenaSood</named-content>
            </collab>
            <collab>
              <named-content content-type="name">Ramanpreet KB</named-content>
            </collab>
            <name>
              <surname>Neerja</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Journal of Oral and Maxillofacial Pathology | Published by Wolters Kluwer – Medknow. 2016</article-title>
        </element-citation>
      </ref>
      <ref id="journal-article-ref-5fd9fec4fb6b9fab81658e22cf0ea13f">
        <element-citation publication-type="journal">
          <issue>3</issue>
          <month>12</month>
          <page-range>194-197</page-range>
          <volume>6</volume>
          <year>2016</year>
          <pub-id pub-id-type="doi">10.1016/j.jobcr.2016.06.002</pub-id>
          <person-group person-group-type="author">
            <name>
              <surname>Gupta</surname>
              <given-names>Vineet</given-names>
            </name>
            <name>
              <surname>Ramani</surname>
              <given-names>Pratibha</given-names>
            </name>
          </person-group>
          <source>Journal of Oral Biology and Craniofacial Research</source>
          <article-title>Histologic and immunohistochemical evaluation of mirror image biopsies in oral squamous cell carcinoma</article-title>
        </element-citation>
      </ref>
      <ref id="journal-article-ref-508a8b59132196f48ee532bdaab49196">
        <element-citation publication-type="journal">
          <day>02</day>
          <issue>1</issue>
          <month>04</month>
          <volume>18</volume>
          <year>2018</year>
          <pub-id pub-id-type="doi">10.1186/s12885-018-4301-1</pub-id>
          <person-group person-group-type="author">
            <name>
              <surname>Xm</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>X </surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Xk</surname>
              <given-names>Z</given-names>
            </name>
            <name>
              <surname>Sj</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>R</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>S</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Df</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Xy</surname>
              <given-names>Z</given-names>
            </name>
            <name>
              <surname>Jl</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Jw</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Dy</surname>
              <given-names>Z</given-names>
            </name>
            <name>
              <surname>Y</surname>
              <given-names>Z</given-names>
            </name>
            <name>
              <surname>Zm</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Ld</surname>
              <given-names>W</given-names>
            </name>
          </person-group>
          <source>BMC cancer</source>
          <article-title>The alterations of cytokeratin and vimentin protein expressions in primary esophageal spindle cell carcinoma</article-title>
        </element-citation>
      </ref>
      <ref id="journal-article-ref-8527e01dd383f3877ee3a3c9946f6c54">
        <element-citation publication-type="journal">
          <issue>5</issue>
          <month>05</month>
          <volume>60</volume>
          <year>2007</year>
          <pub-id pub-id-type="doi">10.1136/jcp.2005.033589</pub-id>
          <person-group person-group-type="author">
            <name>
              <surname>R</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>S</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>S</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>S</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Bc</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>I</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Ak</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <source>Journal of Clinical Pathology</source>
          <article-title>Spindle cell carcinoma of head and neck: an immunohistochemical and molecular approach to its pathogenesis</article-title>
        </element-citation>
      </ref>
      <ref id="journal-article-ref-695d351a6e30938665ee129b544f2fd3">
        <element-citation publication-type="journal">
          <issue>5</issue>
          <month>05</month>
          <page-range>518-522</page-range>
          <volume>59</volume>
          <year>2006</year>
          <pub-id pub-id-type="doi">10.1136/jcp.2005.029991</pub-id>
          <person-group person-group-type="author">
            <name>
              <surname>G</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>S</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>V</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>H</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>A</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>R</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>A</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>P</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Jp</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>C</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>R</surname>
              <given-names>B</given-names>
            </name>
          </person-group>
          <source>Journal of Clinical Pathology</source>
          <article-title>The value of cytokeratin immunohistochemistry in the evaluation of axillary sentinel lymph nodes in patients with lobular breast carcinoma</article-title>
        </element-citation>
      </ref>
      <ref id="journal-article-ref-f57a0fbbda192fbcb2d8b0b789ce029a">
        <element-citation publication-type="journal">
          <day>22</day>
          <issue>12</issue>
          <month>06</month>
          <page-range>4434</page-range>
          <volume>21</volume>
          <year>2020</year>
          <pub-id pub-id-type="doi">10.3390/ijms21124434</pub-id>
          <person-group person-group-type="author">
            <name>
              <surname>V</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>T</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>N</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>K</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Nt</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>M</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <source>International Journal of Molecular Sciences</source>
          <article-title>Analysis of Spatial Distribution and Prognostic Value of Different Pan Cytokeratin Immunostaining Intensities in Breast Tumor Tissue Sections</article-title>
        </element-citation>
      </ref>
      <ref id="journal-article-ref-8d98fdf462e6dbfe057bf6d8bc24e829">
        <element-citation publication-type="journal">
          <day>01</day>
          <issue>3</issue>
          <month>05</month>
          <page-range>e379-e386</page-range>
          <volume>26</volume>
          <year>2021</year>
          <pub-id pub-id-type="doi">10.4317/medoral.24240</pub-id>
          <person-group person-group-type="author">
            <name>
              <surname>Bt </surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Jl</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Dm</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Wp</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Nd</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>M </surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Nh </surname>
              <given-names>C</given-names>
            </name>
            <collab>
              <named-content content-type="name">Rl AJ</named-content>
            </collab>
            <collab>
              <named-content content-type="name">Sf DS</named-content>
            </collab>
            <name>
              <surname>Ac</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Mj</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname> Op</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <source>Medicina Oral, Patologia Oral Y Cirugia Bucal</source>
          <article-title>Primary melanoma of the oral cavity: A multi-institutional retrospective analysis in Brazil</article-title>
        </element-citation>
      </ref>
      <ref id="journal-article-ref-ec27da30267306a52020b4cf39c2285d">
        <element-citation publication-type="journal">
          <day>21</day>
          <issue>23</issue>
          <month>06</month>
          <page-range>3640-3643</page-range>
          <volume>11</volume>
          <year>2005</year>
          <pub-id pub-id-type="doi">10.3748/wjg.v11.i23.3640</pub-id>
          <person-group person-group-type="author">
            <name>
              <surname>Zhou</surname>
              <given-names>Zhi-Wei</given-names>
            </name>
            <name>
              <surname>Rieger</surname>
              <given-names>Nick</given-names>
            </name>
            <name>
              <surname>Ruszkiewicz</surname>
              <given-names>Andrew</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>Guo-Qiang</given-names>
            </name>
            <name>
              <surname>Wan</surname>
              <given-names>De-Sen</given-names>
            </name>
          </person-group>
          <source>World Journal of Gastroenterology</source>
          <article-title>Detection of lymph nodes micrometastases in Dukes' A and B colorectal cancer using anti-cytokeratin antibodies AE1/AE3</article-title>
        </element-citation>
      </ref>
      <ref id="journal-article-ref-f7eb8c059240935685992a14a722a97c">
        <element-citation publication-type="journal">
          <day>1</day>
          <fpage>337</fpage>
          <issue>2</issue>
          <lpage>342</lpage>
          <month>Jan</month>
          <volume>53</volume>
          <year>2012</year>
          <person-group person-group-type="author">
            <collab>
              <named-content content-type="name">Mălin RD</named-content>
            </collab>
            <name>
              <surname>Ioniţă </surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Osman </surname>
              <given-names>I</given-names>
            </name>
            <collab>
              <named-content content-type="name">Mogoantă CA</named-content>
            </collab>
            <name>
              <surname>Cioroianu </surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Ciolofan</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Anghelina</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Enăchescu</surname>
              <given-names>M</given-names>
            </name>
            <collab>
              <named-content content-type="name">Mǎlin RD</named-content>
            </collab>
            <name>
              <surname> Ioniţǎ</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Osman</surname>
              <given-names>I</given-names>
            </name>
          </person-group>
          <source>Rom J Morphol Embryol</source>
          <article-title>Histopathological and immunohistochemical study of laterocervical lymph node metastases of unknown primary origin</article-title>
        </element-citation>
      </ref>
      <ref id="journal-article-ref-7a043012e6147ae43ee9eaa3f73edf31">
        <element-citation publication-type="journal">
          <issue>3</issue>
          <page-range>117-124</page-range>
          <volume>61</volume>
          <year>2004</year>
          <pub-id pub-id-type="doi">10.1080/09674845.2004.11732655</pub-id>
          <person-group person-group-type="author">
            <name>
              <surname>Farrar</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Sandison</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Peston</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Gailani</surname>
              <given-names>M.</given-names>
            </name>
          </person-group>
          <source>British Journal of Biomedical Science</source>
          <article-title>Immunocytochemical analysis of AE1/AE3, CK 14, Ki-67 and p53 expression in benign, premalignant and malignant oral tissue to establish putative markers for progression of oral carcinoma</article-title>
        </element-citation>
      </ref>
      <ref id="journal-article-ref-2b4ab56153a7578cdfea4ea69d0f53c2">
        <element-citation publication-type="journal">
          <issue>1</issue>
          <month>01</month>
          <page-range>25-32</page-range>
          <volume>35</volume>
          <year>2006</year>
          <pub-id pub-id-type="doi">10.1111/j.1600-0714.2005.00366.x</pub-id>
          <person-group person-group-type="author">
            <name>
              <surname>Ranganathan</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Kavitha</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Sawant</surname>
              <given-names>S. S.</given-names>
            </name>
            <name>
              <surname>Vaidya</surname>
              <given-names>M. M.</given-names>
            </name>
          </person-group>
          <source>Journal of Oral Pathology &amp; Medicine: Official Publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology</source>
          <article-title>Cytokeratin expression in oral submucous fibrosis--an immunohistochemical study</article-title>
        </element-citation>
      </ref>
    </ref-list>
  </back>
</article>